Steven A Kaplan, MD
img_Steven A Kaplan
Are you a patient?

The focus of my research initiatives was in enhancing our understanding of the role of various therapies in treating men and women with voiding dysfunction.  More specifically, the role of various medical and minimally invasive therapies for benign prostatic hyperplasia (BPH) was at the core my NIH and clinical grants.  Through these endeavors, the landscape of BPH therapy has changed dramatically over the past 15 years.  Moreover, the role of early intervention, progression of disease and predictive outcomes have served as templates for current thought. The value of combination therapy for many men based on prostate size and symptom profile is now the standard throughout the world. 

In addition, in my role as fellowship director for the past 20 years, I have helped foster an environment of discovery with many of my fellows working in collaboration and creating scientific impact.  More recently, my research has focused on clinical outcomes and economic modeling in various aspects of urologic care and more specifically, Men’s Health.  The role of diabetes, cardiovascular disease and aging on pelvic health emanated from work done with other groups such as the Boston Area Community Health Survey.

At Mount Sinai, my goal is to help build a clinical research infrastructure that will use digital informatics with enhanced uploading of epidemiologic and clinical data among the various entry points in the Men’s Health Network to be created throughout Manhattan.  Longitudinal and dynamic monitoring will allow for the development of predictive treatment algorithms and enhance quality of care and outcomes. 

BS, CUNY Brooklyn College

MD, Icahn School of Medicine at Mount Sinai

MD, Mount Siinai School of Medicine

Residency, Surgery (General Surgery), Mount Sinai Hospital

Residency, Urology, Columbia University Medical Center-Psychiatry GME

Fellowship, Urology, Columbia University Medical Center-Psychiatry GME


American Board of Urology


New York Top Doctors

Castle Connollly/New York Magazine


John K. Lattimer Urology Lifetime Award

Kidney and Urology Foundation


New York Best Doctors

Castle Connolly/New York Magazine


Best Doctors in America

Castle Connolly

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Kaplan during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Aspargo Labs


  • Project Healthcare

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.